Quoin Pharmaceuticals, Ltd. Sponsored ADR (QNRX) – What Are Investment Firms Thinking About This Stock?

Shares of Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) have earned an average rating of “Moderate Buy” from the five research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $17.33.

QNRX has been the topic of several research analyst reports. Canaccord Genuity Group initiated coverage on Quoin Pharmaceuticals in a research note on Monday, October 19th. They issued a “buy” rating and a $18.00 price objective on the stock. BTIG Research assumed coverage on Quoin Pharmaceuticals in a research note on Monday, October 12th. They set a “buy” rating and a $14.00 target price for the company. Lake Street Capital assumed coverage on Quoin Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “buy” rating and a $20.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a report on Friday, October 16th. Finally, Wall Street Zen upgraded shares of Quoin Pharmaceuticals to a “sell” rating in a research note on Saturday, October 17th.

Insider Activity at Quoin Pharmaceuticals

In related news, Director Anthony Culverwell acquired 6,146 shares of the company’s stock in a transaction that occurred on Monday, August 31st. The stock was acquired at an average price of $4.88 per share, with a total value of $29,992.48. Following the purchase, the director directly owned 40,364 shares in the company, valued at approximately $196,976.32. This trade represents a 17.96% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Sally Lawlor bought 10,244 shares of the business’s stock in a transaction on Monday, August 31st. The stock was bought at an average price of $4.88 per share, for a total transaction of $49,990.72. Following the transaction, the chief financial officer directly owned 10,684 shares of the company’s stock, valued at approximately $52,137.92. This represents a 2,328.18% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired 57,370 shares of company stock valued at $279,966 in the last quarter. 7.54% of the stock is owned by company insiders.

Institutional Trading of Quoin Pharmaceuticals

An institutional investor recently raised its position in Quoin Pharmaceuticals stock. SummitTX Capital L.P. grew its position in Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) by 54.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 100,300 shares of the company’s stock after acquiring an additional 35,505 shares during the period. SummitTX Capital L.P. owned 5.56% of Quoin Pharmaceuticals worth $662,000 as of its most recent filing with the SEC. 8.63% of the stock is currently owned by institutional investors.

Quoin Pharmaceuticals Stock Performance

Shares of QNRX stock opened at $4.07 on Monday. The stock’s fifty day moving average price is $5.55 and its two-hundred day moving average price is $5.22. The company has a market cap of $19.52 million, a PE ratio of -0.16 and a beta of 1.56. Quoin Pharmaceuticals has a fifty-two week low of $3.25 and a fifty-two week high of $23.50.

Quoin Pharmaceuticals (NASDAQ:QNRX) last posted its quarterly earnings results on Friday, August 14th. The company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29). On average, equities analysts predict that Quoin Pharmaceuticals will post -7.45 EPS for the current fiscal year.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a clinical-stage specialty pharmaceutical company focused on developing treatments for rare diseases with significant unmet medical needs. The company’s programs are primarily designed to address disorders affecting the skin and other tissues, with an emphasis on topical drug-delivery technologies.

Quoin’s lead product candidate, QRX003, is an investigational topical lotion being developed for Netherton syndrome, a rare genetic skin disorder associated with impaired skin barrier function and inflammation.